Clinical characteristics of patients with ITP receiving decitabine treatment
| . | . | . | . | Antiplatelet antibodies . | . | |
|---|---|---|---|---|---|---|
| Patient no. . | Sex/age (y) . | Platelet count (109/L) . | Course of disease (mo) . | Anti-GPIIb/IIIa . | Anti-GPIb/IX . | Major previous drugs . |
| 1 | M/75 | 6 | 8 | — | ND | Pred, IVIG, Dana |
| 2 | F/74 | 18 | 84 | — | — | IVIG, Pred, RTX |
| 3 | F/29 | 39 | 11 | — | — | Pred, TPO-RA |
| 4 | F/73 | 47 | 12 | — | — | Pred, rhTPO, RTX |
| 5 | M/71 | 1 | 12 | ND | ND | DXM, IVIG |
| 6 | M/38 | 5 | 324 | ND | ND | DXM, IVIG, Dana, RTX |
| 7 | M/19 | 17 | 12 | ND | ND | DXM, IVIG, Dana |
| 8 | M/53 | 16 | 6 | — | + | DXM, Dana |
| 9 | M/56 | 33 | 3 | + | + | DXM, IVIG, TPO-RA |
| 10 | F/50 | 16 | 4 | — | — | DXM, TPO-RA |
| 11 | F/67 | 2 | 12 | ND | ND | DXM, IVIG, rhTPO |
| 12 | M/52 | 11 | 20 | ND | ND | DXM, rhTPO, RTX |
| 13 | M/36 | 2 | 15 | ND | ND | DXM, IVIG, Dana |
| 14 | F/63 | 23 | 144 | — | — | rhTPO, DXM, IVIG, RTX |
| 15 | M/67 | 14 | 30 | — | — | DXM, IVIG, rhIL-11 |
| 16 | F/48 | 5 | 132 | — | — | DXM, rhTPO, SP |
| 17 | M/27 | 1 | 107 | + | — | Pred, IVIG, rhTPO, RTX |
| 18 | F/73 | 8 | 5 | — | — | MP, IVIG, Dana |
| 19 | F/52 | 28 | 240 | — | — | Pred, Dana, VCR, SP |
| 20 | F/57 | 2 | 24 | + | + | Pred, IVIG, Dana |
| 21 | F/52 | 8 | 284 | + | + | Pred, rhTPO, IVIG, CsA, TPO-RA |
| 22 | F/29 | 6 | 84 | — | — | DXM, IVIG, RTX |
| 23 | F/25 | 4 | 48 | ND | ND | DXM, IVIG, RTX |
| 24 | F/19 | 7 | 19 | ND | ND | DXM, rhTPO, IVIG, RTX, VCR |
| 25 | F/17 | 44 | 25 | — | — | DXM, rhTPO, IVIG |
| 26 | M/59 | 1 | 48 | — | — | DXM, rhTPO, IVIG, RTX |
| 27 | F/22 | 9 | 24 | ND | ND | DXM, rhTPO, IVIG |
| 28 | F/41 | 12 | 36 | — | — | DXM, CsA, RTX |
| 29 | M/54 | 6 | 348 | — | + | DXM, rhTPO, IVIG, RTX |
| 30 | M/28 | 1 | 11 | ND | ND | DXM, IVIG, rhTPO, RTX, VCR |
| 31 | F/21 | 6 | 16 | — | + | Pred, IVIG, CsA, rhIL-11 |
| 32 | F/55 | 13 | 12 | + | — | DXM, IVIG, rhTPO |
| . | . | . | . | Antiplatelet antibodies . | . | |
|---|---|---|---|---|---|---|
| Patient no. . | Sex/age (y) . | Platelet count (109/L) . | Course of disease (mo) . | Anti-GPIIb/IIIa . | Anti-GPIb/IX . | Major previous drugs . |
| 1 | M/75 | 6 | 8 | — | ND | Pred, IVIG, Dana |
| 2 | F/74 | 18 | 84 | — | — | IVIG, Pred, RTX |
| 3 | F/29 | 39 | 11 | — | — | Pred, TPO-RA |
| 4 | F/73 | 47 | 12 | — | — | Pred, rhTPO, RTX |
| 5 | M/71 | 1 | 12 | ND | ND | DXM, IVIG |
| 6 | M/38 | 5 | 324 | ND | ND | DXM, IVIG, Dana, RTX |
| 7 | M/19 | 17 | 12 | ND | ND | DXM, IVIG, Dana |
| 8 | M/53 | 16 | 6 | — | + | DXM, Dana |
| 9 | M/56 | 33 | 3 | + | + | DXM, IVIG, TPO-RA |
| 10 | F/50 | 16 | 4 | — | — | DXM, TPO-RA |
| 11 | F/67 | 2 | 12 | ND | ND | DXM, IVIG, rhTPO |
| 12 | M/52 | 11 | 20 | ND | ND | DXM, rhTPO, RTX |
| 13 | M/36 | 2 | 15 | ND | ND | DXM, IVIG, Dana |
| 14 | F/63 | 23 | 144 | — | — | rhTPO, DXM, IVIG, RTX |
| 15 | M/67 | 14 | 30 | — | — | DXM, IVIG, rhIL-11 |
| 16 | F/48 | 5 | 132 | — | — | DXM, rhTPO, SP |
| 17 | M/27 | 1 | 107 | + | — | Pred, IVIG, rhTPO, RTX |
| 18 | F/73 | 8 | 5 | — | — | MP, IVIG, Dana |
| 19 | F/52 | 28 | 240 | — | — | Pred, Dana, VCR, SP |
| 20 | F/57 | 2 | 24 | + | + | Pred, IVIG, Dana |
| 21 | F/52 | 8 | 284 | + | + | Pred, rhTPO, IVIG, CsA, TPO-RA |
| 22 | F/29 | 6 | 84 | — | — | DXM, IVIG, RTX |
| 23 | F/25 | 4 | 48 | ND | ND | DXM, IVIG, RTX |
| 24 | F/19 | 7 | 19 | ND | ND | DXM, rhTPO, IVIG, RTX, VCR |
| 25 | F/17 | 44 | 25 | — | — | DXM, rhTPO, IVIG |
| 26 | M/59 | 1 | 48 | — | — | DXM, rhTPO, IVIG, RTX |
| 27 | F/22 | 9 | 24 | ND | ND | DXM, rhTPO, IVIG |
| 28 | F/41 | 12 | 36 | — | — | DXM, CsA, RTX |
| 29 | M/54 | 6 | 348 | — | + | DXM, rhTPO, IVIG, RTX |
| 30 | M/28 | 1 | 11 | ND | ND | DXM, IVIG, rhTPO, RTX, VCR |
| 31 | F/21 | 6 | 16 | — | + | Pred, IVIG, CsA, rhIL-11 |
| 32 | F/55 | 13 | 12 | + | — | DXM, IVIG, rhTPO |
CsA, cyclosporine; Dana, danazol; DXM, dexamethasone; F, female; GP, glycoprotein; IVIG, intravenous immunoglobulin; M, male; ND, not determined; Pred, prednisone; rhIL-11, recombinant human interleukin-11; rhTPO, recombinant human thrombopoietin; RTX, rituximab; SP, splenectomy; TPO-RA, thrombopoietin receptor agonist; VCR, vincristine.